拜耳Finerenone在与1型糖尿病相关的慢性肾病成人患者中显示出UACR的统计学显著降低-动脉网

Finerenone showed statistically significant reduction of UACR in adults with chronic kidney disease associated with type 1 diabetes

拜耳等信源发布 2025-11-06 22:54



可切换为仅中文







November

十一月

2025

15:49 PM

Europe/Amsterdam

欧洲/阿姆斯特丹

Finerenone showed statistically significant reduction of UACR in adults with chronic kidney disease associated with type 1 diabetes

非奈利酮在与1型糖尿病相关的慢性肾病成人患者中显示出统计学上显著的UACR降低。

Not intended for U.S. and UK Media – Late-Breaking data from FINE-ONE Phase III study presented at ASN Kidney Week 2025

不适用于美国和英国媒体——FINE-ONE三期研究的最新数据在2025年ASN肾脏周上发布。

Summary

摘要

Finerenone is the first medicine in over 30 years to provide positive results in a Phase III study addressing the high risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D) / In the global FINE-ONE Phase III study, finerenone significantly reduced urine albumin-to-creatinine ratio (UACR) by 25% from baseline (ratio to baseline) over 6 months compared to placebo / CKD associated with T1D is a major public health challenge: 30% of people with T1D develop CKD, and CKD associated with T1D significantly increases the risk of kidney failure and cardiovascular events, contributing to CKD being a leading cause of death in T1D / Treatment options in people with CKD associated with T1D are limited, and residual risk remains high in these patients despite guideline-recommended therapies to control hyperglycemia, hypertension, and albuminuria.

Finerenone是30多年来首个在三期临床试验中取得积极结果的药物，该研究针对与1型糖尿病（T1D）相关的慢性肾病（CKD）成年患者，这些患者具有较高的肾脏疾病进展和心血管事件风险。/ 在全球FINE-ONE三期研究中，与安慰剂相比，finerenone在6个月内显著将尿白蛋白肌酐比值（UACR）从基线降低了25%（相对于基线的比率）。/ 与T1D相关的CKD是一项主要的公共卫生挑战：30%的T1D患者会发展为CKD，而与T1D相关的CKD显著增加了肾衰竭和心血管事件的风险，导致CKD成为T1D患者死亡的主要原因之一。/ 对于与T1D相关的CKD患者的治疗选择有限，尽管有指南推荐的控制高血糖、高血压和白蛋白尿的疗法，但这些患者的残余风险仍然很高。

Berlin, November 6, 2025

柏林，2025年11月6日

– Bayer today announced results from the pivotal Phase III FINE-ONE study, demonstrating that finerenone (Kerendia™/ Firialta™) in addition to standard of care is superior to placebo in showing a statistically significant reduction in urine albumin-to-creatinine ratio (UACR) from baseline (ratio to baseline) over 6 months in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D).

– 拜耳今天宣布了关键的 III 期 FINE-ONE 研究的结果，证明在标准治疗基础上，finerenone（Kerendia™/Firialta™）相较于安慰剂，在患有与 1 型糖尿病（T1D）相关的慢性肾病（CKD）成人患者中，能够在 6 个月内显著降低尿白蛋白肌酐比值（UACR）基线水平（与基线的比率），并具有统计学意义。

Elevated UACR is associated with a higher risk of kidney disease progression and kidney failure, and is a predictor of cardiovascular events. Reduction of UACR with finerenone in the pivotal Phase III studies in CKD in type 2 diabetes (FIDELIO-DKD, FIGARO-DKD) was strongly associated with delay of kidney disease progression and kidney failure, as well as with a reduction of cardiovascular events.

尿白蛋白/肌酐比值 (UACR) 升高与较高的肾脏疾病进展和肾衰竭风险相关，并且是心血管事件的预测因子。在慢性肾脏病（CKD）合并2型糖尿病的III期关键研究（FIDELIO-DKD、FIGARO-DKD）中，使用非奈利酮降低UACR与延缓肾脏疾病进展和肾衰竭以及减少心血管事件密切相关。

The FINE-ONE findings were presented today as “Featured High-Impact Clinical Trial” during the Opening Plenary session of the American Society of Nephrology’s (ASN) Kidney Week 2025..

FINE-ONE 研究结果今天在美国肾脏病学会 (ASN) 2025 年肾脏周的开幕全体会议上作为“高影响力临床试验”展示。

“Patients living with type 1 diabetes and chronic kidney disease face an increased risk of kidney failure and cardiovascular disease, impacting quality of life and life expectancy,” said Hiddo Lambers Heerspink, Professor of Clinical Trials and Personalized Medicine at the University Medical Center Groningen, Netherlands, and Chair of the study’s Steering Committee.

“患有1型糖尿病和慢性肾病的患者面临肾衰竭和心血管疾病风险的增加，影响生活质量和预期寿命，”荷兰格罗宁根大学医学中心临床试验与个性化医学教授、该研究指导委员会主席希多·兰伯斯·赫尔平克表示。

“UACR reduction is highly correlated with a reduction in kidney and cardiovascular events. The positive results of the FINE-ONE study represent a landmark moment and give hope to patients with chronic kidney disease associated with type 1 diabetes who currently have very limited treatment options.”.

“UACR 的降低与肾脏和心血管事件的减少高度相关。FINE-ONE 研究的积极结果代表了一个里程碑式的时刻，为目前治疗选择非常有限的 1 型糖尿病相关慢性肾病患者带来了希望。”

In FINE-ONE, finerenone significantly reduced the primary endpoint of relative change in UACR by 25% (percentage reduction, least squares geometric mean (LSGM) ratio 0.75 [95% CI, 0.65-0.87; p=0.0001]) from baseline over 6 months versus placebo. At any time post-baseline, 81 out of 119 participants (68.1%) in the finerenone arm, versus 54 out of 116 participants (46.6%) in the placebo arm achieved at least a 30% reduction in UACR, a threshold established by the American Diabetes Association (ADA) as being associated with slower CKD progression in patients with CKD associated with type 2 diabetes.

在FINE-ONE试验中，与安慰剂相比，非奈利酮在6个月内显著降低了尿白蛋白肌酐比值（UACR）相对变化的主要终点，降幅达25%（百分比减少，最小二乘几何平均(LSGM)比值为0.75 [95% CI, 0.65-0.87; p=0.0001]）。在基线后的任何时间点，非奈利酮组119名参与者中有81人（68.1%）达到了至少30%的UACR降低，而安慰剂组116名参与者中有54人（46.6%）达到该标准。美国糖尿病协会（ADA）设定这一阈值，认为其与2型糖尿病相关慢性肾病（CKD）患者的CKD进展减缓相关。

Based on the outcome of FINE-ONE, the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone is the first medicine since the 1990s to provide positive results in a Phase III study addressing the high risk of kidney disease progression and cardiovascular events in patients with CKD associated with T1D..

基于 FINE-ONE 的结果，非甾体类盐皮质激素受体拮抗剂（nsMRA）finerenone 是自 1990 年代以来首个在 III 期研究中取得积极成果的药物，该研究针对与 T1D 相关的 CKD 患者肾脏疾病进展和心血管事件的高风险。

'People with type 1 diabetes and chronic kidney disease face an immense burden due to their increased risk for both kidney and cardiovascular events,' said Jonathan Rosen, PhD, Research Director at Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization. 'Breakthrough T1D remains committed to collaborating with Bayer to improve kidney care for people with type 1 diabetes.'.

“1型糖尿病和慢性肾病患者由于肾脏和心血管事件的风险增加，面临着巨大的负担，”全球领先的1型糖尿病研究与倡导组织Breakthrough T1D的研究总监乔纳森·罗森（Jonathan Rosen）博士表示，“Breakthrough T1D将继续与拜耳合作，改善1型糖尿病患者的肾脏护理。”

CKD affects 30% of people with T1D and approximately one in four of these individuals will progress to end-stage kidney disease. In 2025, more than 9.5 million people are living with T1D worldwide, with prevalence projected to rise to between 13.5 - 17.4 million in 2040. People with both T1D and CKD face a significantly increased risk of kidney failure and cardiovascular disease (CVD).

慢性肾病（CKD）影响30%的1型糖尿病（T1D）患者，其中约四分之一的人会进展为终末期肾病。到2025年，全球将有超过950万人患有1型糖尿病，预计患病率将在2040年上升至1350万至1740万之间。同时患有1型糖尿病和慢性肾病的人面临显著增加的肾衰竭和心血管疾病（CVD）风险。

In the U.S., 1.4 million adults aged 20 years or older are living with type 1 diabetes, representing 5.2% of all US adults with diagnosed diabetes. More than half of new T1D diagnoses in the U.S. occur in people aged 20 and older, and around 85% of these cases arise in people with no known family history of the condition..

在美国，有 140 万名 20 岁及以上的成年人患有 1 型糖尿病，占美国已确诊糖尿病成人总数的 5.2%。美国超过一半的新发 1 型糖尿病诊断出现在 20 岁及以上的人群中，其中约 85% 的病例发生在没有已知家族病史的人群中。

“UACR is an important predictor of kidney and cardiovascular events in chronic kidney disease associated with diabetes, with elevated levels indicating worsening kidney damage. For more than three decades, no kidney-specific disease modifying therapies have been approved in chronic kidney disease associated with type 1 diabetes,” said Dr.

“UACR 是糖尿病相关慢性肾病患者肾脏和心血管事件的重要预测因子，其水平升高表明肾脏损害正在恶化。三十多年来，一直没有针对 1 型糖尿病相关慢性肾病的肾脏特异性疾病改善疗法获批，”博士说道。

Christian Rommel, Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “Finerenone has demonstrated its ability to reduce UACR in patients with CKD associated with T1D, and we are excited about the prospect of offering a potential new treatment option for these patients, whose condition has been under-researched for so long.”.

拜耳制药部门全球研发主管克里斯蒂安·罗梅尔表示：“Finerenone 已证明其在与 T1D 相关的 CKD 患者中降低 UACR 的能力，我们对于为这些长期以来研究不足的患者提供潜在的新治疗选择感到非常兴奋。”

The results of the FINE-ONE study are consistent with and add to the robust body of evidence of finerenone, showing a significant reduction in UACR over 6 months. There is a strong association between elevated UACR (albuminuria) and kidney disease progression in both types of diabetes, and UACR reduction is highly correlated with a reduction in kidney and cardiovascular events.

FINE-ONE 研究的结果与非奈利酮的有力证据一致，并进一步补充了这一证据，显示在6个月内尿白蛋白/肌酐比值 (UACR) 显著降低。无论是哪种类型的糖尿病，UACR（白蛋白尿）升高与肾脏疾病进展之间存在很强的关联，而 UACR 的降低与肾脏和心血管事件的减少高度相关。

Data from the FIDELITY pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD studies in patients with CKD associated with type 2 diabetes showed that more than 80% of the kidney benefit of finerenone was explained by UACR reduction. Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) targeting MR and renin-angiotensin-aldosterone system (RAAS) overactivation.

FIDELITY汇集了FIDELIO-DKD和FIGARO-DKD三期研究的数据，这些研究针对与2型糖尿病相关的CKD患者，数据显示，超过80%的finerenone肾脏益处可由UACR的降低来解释。Finerenone是一种非甾体类、选择性盐皮质激素受体拮抗剂（nsMRA），靶向MR和肾素-血管紧张素-醛固酮系统（RAAS）的过度激活。

MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, as well as inflammatory and fibrotic factors..

MR过度激活会导致慢性肾病（CKD）进展和心血管损伤，这可能是由代谢、血液动力学以及炎症和纤维化因素驱动的。

Finerenone was well-tolerated in the FINE-ONE study, which is consistent with the well-established safety profile of finerenone. No new safety signals were identified. The overall incidence of treatment-emergent serious adverse events was comparable between finerenone and placebo groups. Hyperkalemia-related adverse events occurred more frequently with finerenone than placebo (in 12 patients or 10.1% in the finerenone arm, versus in 4 patients or 3.3% in the placebo arm, respectively).

在FINE-ONE研究中，非奈利酮表现出了良好的耐受性，这与非奈利酮已确立的安全性特征一致。未发现新的安全性信号。非奈利酮组和安慰剂组之间，治疗期间出现的严重不良事件总体发生率相当。与安慰剂相比，非奈利酮组中与高钾血症相关的不良事件发生频率更高（非奈利酮组中有12名患者，占10.1%，安慰剂组中有4名患者，占3.3%）。

There were no fatal adverse events of hyperkalemia in either treatment group, and the rate of hospitalization or discontinuation due to hyperkalemia was low..

两个治疗组均未发生高钾血症的严重不良事件，因高钾血症导致的住院或停药率较低。

Bayer plans to provide the data to health authorities for regulatory assessment of finerenone for the treatment of CKD associated with T1D in due course.

拜耳计划适时向卫生当局提供数据，以对 finerenone 治疗与 T1D 相关的 CKD 进行监管评估。

About Kerendia

关于Kerendia

™

/ Firialta

/ 菲里阿尔塔

™

(finerenone)

（非奈酮）

Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors..

Kerendia™ 和 Firialta™ 是 finerenone 的全球保护商标。Finerenone 是一种非甾体类、选择性盐皮质激素受体 (MR) 拮抗剂，已被证明可以阻断 MR 过度激活的有害影响。MR 过度激活会促进慢性肾病 (CKD) 的进展和心血管损伤，而这些可能由代谢、血流动力学或炎症和纤维化因素驱动。

Finerenone is marketed as Kerendia™ or, in some countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 95 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in the U.S..

Finerenone 以 Kerendia™ 或在某些国家以 Firialta™ 的名称上市，已被全球 95 个国家以上（包括中国、欧洲、日本和美国）批准用于治疗与 2 型糖尿病 (T2D) 相关的慢性肾病 (CKD) 成年患者。Finerenone 还在美国被批准用于治疗左心室射血分数 (LVEF) ≥ 40% 的心力衰竭患者。

The clinical study program with finerenone, FINEOVATE, currently comprises ten Phase III studies with dedicated programs in HF and CKD respectively. The MOONRAKER program includes the completed pivotal Phase III study FINEARTS-HF, as well as the ongoing collaborative, investigator-sponsored studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF.

目前，正在进行的非奈利酮临床研究项目FINEOVATE包括十个III期研究，分别针对心力衰竭（HF）和慢性肾病（CKD）的专门项目。MOONRAKER项目包括已完成的关键性III期研究FINEARTS-HF，以及正在进行的合作性、研究者发起的研究REDEFINE-HF、CONFIRMATION-HF和FINALITY-HF。

The THUNDERBALL CKD program consists of the completed Phase III studies FIDELIO-DKD, FIGARO-DKD, and FINE-ONE, and the Phase II study CONFIDENCE; as well as the ongoing Phase III studies FIND-CKD, FIONA, and FIONA-OLE..

THUNDERBALL CKD项目包括已完成的III期研究FIDELIO-DKD、FIGARO-DKD和FINE-ONE，以及II期研究CONFIDENCE；还包括正在进行的III期研究FIND-CKD、FIONA和FIONA-OLE。

About FINE-ONE

关于FINE-ONE

In FINE-ONE, 242 participants were randomized from more than 80 sites across 9 countries worldwide to receive either finerenone or placebo once daily. In addition, patients in the study received usual therapy to treat symptoms and comorbidities.

在 FINE-ONE 研究中，来自全球 9 个国家超过 80 个中心的 242 名参与者被随机分配接受每日一次非奈利酮或安慰剂治疗。此外，研究中的患者还接受了常规治疗以缓解症状和合并症。

In FINE-ONE, finerenone significantly reduced the primary endpoint of relative change in UACR by 25% (percentage reduction, least squares geometric mean (LSGM) ratio 0.75 [95% CI, 0.65-0.87; p=0.0001]) from baseline over 6 months versus placebo. At any time post-baseline, 81 out of 119 participants (68.1%) in the finerenone arm, versus 54 out of 116 (46.6%) participants in the placebo arm achieved at least a 30% reduction in UACR, a threshold established by the American Diabetes Association (ADA) as being associated with slower CKD progression in patients with CKD associated with type 2 diabetes.

在FINE-ONE试验中，与安慰剂相比，非奈利酮在6个月内使尿白蛋白肌酐比值（UACR）相对变化的主要终点显著降低了25%（百分比减少，最小二乘几何平均(LSGM)比值为0.75 [95% CI, 0.65-0.87; p=0.0001]）。在基线后的任何时间点，非奈利酮组的119名参与者中有81人（68.1%）达到了至少30%的UACR降低，而安慰剂组的116名参与者中有54人（46.6%）达到此标准。这一阈值由美国糖尿病协会（ADA）确立，与2型糖尿病相关的慢性肾病（CKD）患者的CKD进展减缓相关。

The safety profile of finerenone in FINE-ONE was consistent with previous studies and no new safety signals were identified..

FINE-ONE 研究中 finerenone 的安全性特征与之前的研究一致，未发现新的安全性信号。

FINE-ONE is a global, randomized, placebo-controlled, double-blind, multicenter Phase III study in people with CKD and T1D. The primary objective was to demonstrate whether the addition of finerenone to standard of care is superior to placebo in reducing UACR from baseline over six months. Secondary endpoints included the number of participants with treatment emergent adverse events and hyperkalemia (adverse event of special interest)..

FINE-ONE 是一项全球性、随机、安慰剂对照、双盲、多中心的 III 期研究，针对患有 CKD 和 T1D 的人群。主要目标是证明在标准治疗中加入非奈利酮是否在六个月内比安慰剂更有效地减少 UACR 基线水平。次要终点包括出现治疗相关不良事件和高钾血症（特别关注的不良事件）的参与者人数。

Participants were randomly assigned 1:1 to finerenone (10 or 20 mg OD) or a finerenone-matched placebo. The starting dose depended on estimated glomerular filtration rate (eGFR) level (10 mg for eGFR ≥25–<60 mL/min/1.73 m

参与者以1:1的比例随机分配到finerenone（10或20 mg 每日一次）或与finerenone匹配的安慰剂组。起始剂量取决于估算的肾小球滤过率（eGFR）水平（eGFR ≥25–<60 mL/min/1.73 m时为10 mg）。

; 20 mg for eGFR ≥60 mL/min/1.73 m

；对于eGFR ≥60 mL/min/1.73 m，剂量为20 mg

. Finerenone was uptitrated to the 20 mg target dose after 30 days if the serum/plasma [K+] is ≤4.8 mmol/L and the eGFR decrease is <30% compared with the value measured at the prior visit. Safety was assessed at all scheduled visits, including serum potassium determined both centrally and locally. Blood pressure was assessed at screening and all follow-up visits.

如果血清/血浆[K+] ≤4.8 mmol/L，且与前次访视测量值相比eGFR下降<30%，则在30天后将Finerenone上调至20 mg目标剂量。在所有预定访视中评估安全性，包括中心和本地测定的血清钾。血压在筛查和所有随访访视时进行评估。

UACR was assessed at screening, baseline, month 3, month 6 and at the follow-up visit one month post treatment..

UACR 在筛查、基线、第 3 个月、第 6 个月以及治疗后一个月的随访中进行了评估。

About Chronic Kidney Disease associated with Type 1 Diabetes

关于与1型糖尿病相关的慢性肾病

Type 1 Diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of pancreatic beta cells leading to insulin deficiency and requiring lifelong insulin treatment. Among the US population overall, crude estimates for 2018 indicated that 1.4 million adults aged 20 years or older (or 5.2% of all US adults with diagnosed diabetes), reported both having T1D and using insulin..

1型糖尿病（T1D）是一种慢性自身免疫性疾病，其特征是胰腺β细胞被破坏，导致胰岛素缺乏，并需要终身使用胰岛素治疗。据2018年的粗略估计数据显示，在美国20岁及以上的成年人中，有140万人（占所有已确诊糖尿病的美国成年人的5.2%）报告既患有1型糖尿病又在使用胰岛素。

CKD is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease..

慢性肾脏病（CKD）是一种常见且可能致命的疾病，广泛存在但未被充分认识。CKD在无声无息中进展，且难以预测，许多症状在疾病晚期才会显现。CKD是糖尿病最常见的并发症之一，同时也是心血管疾病的独立风险因素。

CKD affects 30% of people with T1D. In a systematic analysis for the Global Burden of Disease study, it was reported that the prevalence of CKD associated with T1D had increased by 58.2% from 1990 to 2007 and by 21.7% from 2007 to 2017. The 2017 global prevalence of CKD due to T1D was an estimated 32.5 per 100,000 individuals..

慢性肾病影响30%的1型糖尿病患者。在《全球疾病负担研究》的一次系统分析中，据报道，与1型糖尿病相关的慢性肾病患病率从1990年到2007年增加了58.2%，从2007年到2017年增加了21.7%。据估计，2017年因1型糖尿病导致的慢性肾病的全球患病率为每10万人中有32.5人。

The clinical course of CKD in people with T1D is characterized by an increased urinary albumin excretion rate, which is a first sign of kidney damage and may progress to macroalbuminuria and decrease in kidney function as measured by estimated glomerular filtration rate (eGFR). The treatment of T1D consists of insulin treatment to control hyperglycemia.

1型糖尿病（T1D）患者的慢性肾脏病（CKD）临床过程表现为尿白蛋白排泄率增加，这是肾脏损伤的首要迹象，可能进展为大量白蛋白尿，并导致通过估算肾小球滤过率（eGFR）测量的肾功能下降。T1D的治疗包括通过胰岛素治疗来控制高血糖。

In people with T1D, blood glucose intervention targeting HbA1c levels ≤7% can slow onset and progression of kidney disease. Despite guideline-recommended treatment with ACEIs and ARBs, residual risk remains high in people with CKD and T1D, with up to a quarter progressing to end-stage-kidney-disease.

在T1D患者中，针对HbA1c水平≤7%的血糖干预可以减缓肾脏疾病的发作和进展。尽管按照指南推荐使用ACEI和ARB进行治疗，但CKD和T1D患者的残余风险仍然很高，多达四分之一的患者会进展为终末期肾病。

CKD associated with T1D significantly increases the risk of cardiovascular events and kidney failure, contributing to CKD being a leading cause of death in T1D..

与1型糖尿病相关的慢性肾脏病显著增加心血管事件和肾衰竭的风险，是导致1型糖尿病患者死亡的主要原因之一。

About Bayer’s Commitment in Cardiovascular and Kidney Diseases

关于拜耳在心血管和肾脏疾病方面的承诺

Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The strategy is to unlock the strong potential of the future cardiovascular market by transforming Bayer’s portfolio into precision cardiology, addressing the high disease burden, and driving long-term growth.

拜耳在心脏病学领域处于领先地位，并正在推进一系列创新治疗方案。心脏和肾脏在健康和疾病中密切相关，拜耳正致力于开发针对心血管和肾脏疾病的新的治疗方法，以满足尚未满足的医疗需求。其战略是通过将拜耳的产品组合转型为精准心脏病学，释放未来心血管市场的巨大潜力，应对高疾病负担，并推动长期增长。

Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated..

拜耳的产品组合已经包括几种创新产品和化合物，它们处于临床前和临床开发的不同阶段。这些产品共同反映了公司的研究方法，即优先考虑有可能影响心血管疾病治疗方式的靶点和通路。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在全球范围内拥有医疗保健和营养等生命科学领域核心竞争力的企业。秉承“人人健康，无饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于推动可持续发展，并通过其业务产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2024财年，集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用达62亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com

关注我们的Facebook：

http://www.facebook.com/bayer

在 Twitter 上关注我们：

@BayerPharma

@拜耳制药

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来结果、财务状况、发展或业绩与这里提供的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，这些报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担更新这些前瞻性声明或使其符合的任何责任 whatsoever

them to future events or developments.

将它们应用于未来的事件或发展。

Contacts

联系人

Dr. Daniela Esser

丹妮拉·艾瑟博士